---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-001061"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2024-01-10T23:59:59+00:00"
generated_at: "2026-06-07T00:47:44.397950+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics licenses azer-cel, reports preliminary Q4 BRIUMVI revenue $40M, FY2024 guidance $220-260M

## Summary
- Upfront payment to Precision: $7.5M ($5.25M cash + $2.25M equity); deferred $2.5M equity; up to $288M milestone payments plus high-single-digit to low-double-digit royalties.
- Preliminary Q4 2023 BRIUMVI U.S. net product revenue ~$40M, full year ~$89M; year-end cash ~$215M.
- 2024 guidance: BRIUMVI U.S. net product revenue target $220-260M, Q1 target $41-46M; operating expense ~$250M.
- 2024 pipeline milestones: start trials for subcutaneous BRIUMVI, BRIUMVI in other autoimmune diseases, and azer-cel in autoimmune disease.

## SEC filing metadata
- accession: 0001437749-24-001061
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2024-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/0001437749-24-001061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/tgtx20240109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-001061
- JSON: https://secwatch.observer/filing/0001437749-24-001061.json
- Plain text: https://secwatch.observer/filing/0001437749-24-001061.txt

## Key facts
- Material Agreements
  TG THERAPEUTICS, INC. entered into License Agreement with Precision BioSciences, Inc. valued at $7.5 million (effective 2024-01-07).
  - Action: entry
  - Agreement: license
  - Counterparty: Precision BioSciences, Inc.
  - Value: $7.5 million
  - Effective: 2024-01-07
  source text: On January 7, 2024, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into a License Agreement (the “License Agreement”) with Precision BioSciences, Inc. (“Precision”), pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (“azer-cel”) for the treatment of autoimmune and other non-oncology diseases and conditions (collectively, the “Field”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774924001061/0001437749-24-001061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.